Erratum: Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer (British Journal of Cancer (2014) 110 (2855-2864) DOI: 10.1038/bjc.2014.232);Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer

British Journal of Cancer

Volumn 110, Issue 12, 2014, Pages 2855-2864

  Soh, C L ^a   McNeil, K ^a   Owczarek, C M ^b   Hardy, M P ^b   Fabri, L J ^b   Pearse, M ^b   Delaine, C A ^a,c   Forbes, B E ^a,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CSL LIMITED   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Breast cancer; IGFBP; Insulin like growth factor; Vascularisation; Xenograft

Indexed keywords

FIBRONECTIN; INTERSTITIAL COLLAGENASE; MATRILYSIN; PROTEINASE; RECOMBINANT PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; TAMOXIFEN; VITRONECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; EXTRACELLULAR MATRIX; FEMALE; HT 29 CELL LINE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MCF 7 CELL LINE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; BINDING SITES; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902550007     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.385     Document Type: Erratum

References (57)

1. Alami N, Page V, Yu Q, Jerome L, Paterson J, Shiry L, Leyland-Jones B (2008) Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res 18(6): 487-496
2. Arai T, Parker A, Busby Jr W, Clemmons DR (1994) Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J Biol Chem 269(32): 20388-20393. (Pubitemid 24260439
3. Attias-Geva Z, Bentov I, Ludwig DL, Fishman A, Bruchim I, Werner H (2011) Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells. Eur J Cancer 47(11): 1717-1726
4. AzarWJ, Azar SH, Higgins S, Hu JF, Hoffman AR, Newgreen DF,Werther GA, Russo VC (2011) IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology 152(9): 3332-3342
5. Bach LA, Headey SJ, Norton RS (2005) IGF-binding proteins-The pieces are falling into place. Trends Endocrinol Metab 16(5): 228-234. (Pubitemid 40853886
6. Belfiore A, Malaguarnera R (2011) Insulin receptor and cancer. Endocr Relat Cancer 18(4): R125-R147
7. Bhat TA, Singh RP (2008) Tumor angiogenesis-A potential target in cancer chemoprevention. Food Chem Toxicol 46(4): 1334-1345. (Pubitemid 351258200
8. Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ (2013) Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy. Clin Cancer Res 19(11): 2984-2994
9. Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ (2012) Potent inhibition of angiogenesis by the IGF-1 receptor-Targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther 11(3): 649-659
10. Carrick FE, Forbes BE, Wallace JC (2001) BIAcore analysis of bovine insulinlike growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino-And carboxyl-Terminal domains. J Biol Chem 276(29): 27120-27128
11. Clemmons DR (2007) Modifying IGF1 activity: An approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6(10): 821-833
12. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-Type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11(5): 2063-2073. (Pubitemid 40471873
13. Conover CA, Khosla S (2003) Role of extracellular matrix in insulin-like growth factor (IGF) binding protein-2 regulation of IGF-II action in normal human osteoblasts. Growth Horm IGF Res 13(6): 328-335. (Pubitemid 37493323
14. Contois LW, Nugent DP, Caron JM, Cretu A, Tweedie E, Akalu A, Liebes L, Friesel R, Rosen C, Vary C, Brooks PC (2012) Insulin-like growth factor binding protein-4 differentially inhibits growth factor-induced angiogenesis. J Biol Chem 287(3): 1779-1789
15. Culouscou JM, Remacle-Bonnet M, Garrouste F, Fantini J, Marvaldi J, Pommier G (1990) Production of insulin-like growth factor II (IGF-II) and different forms of IGF-binding proteins by HT-29 human colon carcinoma cell line. J Cell Physiol 143(3): 405-415
16. Degraff DJ, Aguiar AA, Sikes RA (2009) Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res 1(2): 115-130
17. Delafontaine P, Song YH, Li Y (2004) Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 24(3): 435-444. (Pubitemid 38326135
18. Denley A, Brierley GV, Carroll JM, Lindenberg A, Booker GW, Cosgrove LJ, Wallace JC, Forbes BE, Roberts Jr CT (2006) Differential activation of insulin receptor isoforms by insulin-like growth factors is determined by the C domain. Endocrinology 147(2): 1029-1036. (Pubitemid 43113023
19. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE (2005) Molecular interactions of the IGF system. Cytokine Growth Factor Rev 16(4-5): 421-439. (Pubitemid 41022012
20. Denley A, Wallace JC, Cosgrove LJ, Forbes BE (2003) The insulin receptor isoform exon 11-(IR-A) in cancer and other diseases: A review. Horm Metab Res 35(11-12): 778-785. (Pubitemid 38058183
21. Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, Xiao X, Peat TS, Newman J, Pilling PA, Phan T, Priebe I, Brierley GV, Kastrapeli N, Kopacz K, Martik D, Wassaf D, Rank D, Conley G, Huang Y, Adams TE, Cosgrove L (2010) A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Mol Cancer Ther 9(6): 1809-1819
22. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23(6): 824-854. (Pubitemid 35454590
23. Forbes BE, McCarthy P, Norton RS (2012) Insulin-like growth factor binding proteins: A structural perspective. Front Endocrinol (Lausanne) 3: 38
24. Forbes BE, Turner D, Hodge SJ, McNeil KA, Forsberg G, Wallace JC (1998) Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-Terminal domain. J Biol Chem 273(8): 4647-4652. (Pubitemid 28103210
25. Foulstone EJ, Zeng L, Perks CM, Holly JM(2013) Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: Novel regulation of the estrogen receptor. Endocrinology 154(5): 1780-1793
26. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R (2008) The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114(1): 23-37. (Pubitemid 351998752
27. Galea CA, Mobli M, McNeil KA, Mulhern TD, Wallace JC, King GF, Forbes BE, Norton RS (2012) Insulin-like growth factor binding protein-2: NMR analysis and structural characterisation of the N-Terminal domain. Biochimie 94: 608-616
28. Gustavsson H, Tesan T, Jennbacken K, Kuno K, Damber JE, Welen K (2010) ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors. BMC Cancer 10: 288
29. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L (2013) Matrix metalloproteinases in cancer: Their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 34(4): 2041-2051
30. Headey SJ, Leeding KS, Norton RS, Bach LA (2004) Contributions of the N-And C-Terminal domains of IGF binding protein-6 to IGF binding. J Mol Endocrinol 33(2): 377-386
31. Jones JI, Gockerman A, Busby Jr WH, Camacho-Hubner C, Clemmons DR (1993) Extracellular matrix contains insulin-like growth factor binding protein-5: Potentiation of the effects of IGF-I. J Cell Biol 121(3): 679-687
32. Kashyap AS, Hollier BG, Manton KJ, Satyamoorthy K, Leavesley DI, Upton Z (2011) Insulin-like growth factor-I:vitronectin complex-induced changes in gene expression effect breast cell survival and migration. Endocrinology 152(4): 1388-1401
33. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P (2007) Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 26(12): 1811-1819. (Pubitemid 46426204
34. Liu C, Shao ZM, Zhang L, Beatty P, Sartippour M, Lane T, Livingston E, Nguyen M (2001) Human endomucin is an endothelial marker. Biochem Biophys Res Commun 288(1): 129-136. (Pubitemid 32999736
35. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JKV, Sawyers CL (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 104(13): 5563-5568. (Pubitemid 47175720
36. Menouny M, Binoux M, Babajko S (1997) Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: Modulation by transforming growth factor-beta and retinoic acid. Endocrinology 138(2): 683-690. (Pubitemid 27110919
37. Menu E, Jernberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O, Axelson M, Asosingh K, Nilsson K, Van Camp B, Vanderkerken K (2006) Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: An in vitro and in vivo study in the 5T33MMmouse model. Blood 107(2): 655-660. (Pubitemid 43076391
38. Miyamoto S, Nakamura M, Yano K, Ishii G, Hasebe T, Endoh Y, Sangai T, Maeda H, Shi chuang Z, Chiba T (2007) Matrix metalloproteinase 7 triggers the matricrine action of insulin like growth factor II via proteinase activity on insulin like growth factor binding protein 2 in the extracellular matrix. Cancer Sci 98(5): 685-691
39. Morgan H, Hill PA (2005) Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. Cancer Cell Int 5(1): 1
40. Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK, Stoeltzing O (2008) Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer 44(11): 1577-1586
41. Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, Stampfer MJ, Clinton SK (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27(33): 5627-5633
42. Oh S-H, KimW-Y, Lee O-H, Kang J-H, Woo J-K, Kim J-H, Glisson B, Lee H-Y (2012) Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma. Cancer Sci 103(7): 1259-1266
43. Ojima Y, Hongo A, Liu Y, Zhu L, Kusumoto T, Nakamura K, Seki N, Hiramatsu Y (2012) Antitumor effects of novel shorter truncated insulinlike growth factor I receptors. Cancer Biol Ther 13(7): 559-566
44. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 12(3): 159-169
45. Rajah R, Khare A, Lee PD, Cohen P (1999) Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol 163(3): 487-494. (Pubitemid 30033744
46. Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA (2009) Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 4(11): E7669
47. Rosenzweig SA, Atreya HS (2010) Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 80(8): 1115-1124
48. Russo VC, Schutt BS, Andaloro E, Ymer SI, Hoeflich A, Ranke MB, Bach LA, Werther GA (2005) Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146(10): 4445-4455. (Pubitemid 41324043
49. Ryan AJ, Napoletano S, Fitzpatrick PA, Currid CA, O'Sullivan NC, Harmey JH (2009) Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer. Br J Cancer 101(2): 278-286
50. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R, Belfiore A (1999) Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism. Oncogene 18(15): 2471-2479. (Pubitemid 29206160
51. Sitar T, Popowicz GM, Siwanowicz I, Huber R, Holak TA (2006) Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci USA 103(35): 13028-13033. (Pubitemid 44338911
52. So AI, Levitt RJ, Eigl B, Fazli L,MuramakiM, Leung S, CheangMCU, Nielsen TO, Gleave M, Pollak M (2008) Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14(21): 6944
53. Stefater 3rd JA, Lewkowich I, Rao S, Mariggi G, Carpenter AC, Burr AR, Fan J, Ajima R, Molkentin JD, Williams BO, Wills-Karp M, Pollard JW, Yamaguchi T, Ferrara N, Gerhardt H, Lang RA (2011) Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature 474(7352): 511-515
54. Takahara K, Ibuki N, Ghaffari M, Tearle H, Ong CJ, Azuma H, Gleave ME, Pollak M, Cox ME (2013) The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice. Prostate Cancer Prostatic Dis 16(3): 239-247
55. Wang N, Lu Y, Pinard M, Pilotte A, Gilbert R, Massie B, Brodt P (2013) Sustained production of a soluble IGF-I receptor by gutless adenovirustransduced host cells protects from tumor growth in the liver. Cancer Gene Ther 20(4): 229-236
56. Yee D (2012) Insulin-like growth factor receptor inhibitors: Baby or the bathwater?. J Natl Cancer Inst 104(13): 975-981
57. Zhang C, Lu L, Li Y, Wang X, Zhou J, Liu Y, Fu P, Gallicchio MA, Bach LA, Duan C (2012) IGF binding protein-6 expression in vascular endothelial cells is induced by hypoxia and plays a negative role in tumor angiogenesis. Int J Cancer 130(9): 2003-2012.